I Przychodnia Lekarska Komed Roman Karaszewski II Osrodek Badan Klinicznych III Restauracja Rogatka Roman Karaszewski

At I Przychodnia Lekarska Komed Roman Karaszewski II Osrodek Badan Klinicznych III Restauracja Rogatka Roman Karaszewski, investigators are evaluating new immunotherapy combinations for metastatic castration‑resistant prostate cancer. The goal is to improve overall survival and delay disease progression by adding checkpoint inhibition to standard androgen‑targeted therapy.

• Immune checkpoint inhibitor plus androgen receptor antagonist
• Overall survival as primary outcome
• Radiographic progression‑free survival evaluation

These studies aim to offer patients more effective treatment options and generate evidence for future standards of care in advanced prostate cancer.

Research at the clinic focuses on advanced breast cancer subtypes, including HER2‑Positive, PIK3CA‑mutated and HR‑Positive, HER2‑Negative disease. Trials test novel targeted agents such as inavolisib and gedatolisib in combination with established therapies to extend progression‑free survival after prior CDK4/6 inhibitor treatment.

• Targeted PI3K pathway inhibition
• Maintenance therapy following first‑line induction
• Combination strategies after CDK4/6 inhibitor resistance

The work supports personalized medicine by identifying which patients benefit most from specific molecularly directed regimens.

The site also integrates environmental and public health considerations into its clinical research program, ensuring that patient safety and community well‑being are central to trial conduct. By monitoring local environmental factors and providing education, the clinic contributes to broader health promotion in Konin.

• Assessment of environmental risk factors in trial participants
• Community outreach and health education
• Collaboration with local health authorities

This holistic approach reflects the institution’s commitment to delivering high‑quality care while safeguarding public health.